DCTHDelcath Systems, Inc.
Is the price fair?
Modest expectations priced in. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
Priced for ~10% a year FCF growth. The price demands less than its three-year revenue growth of 231% a year, expectations look modest.
Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.
What DCTH's price assumes
Delcath Systems, Inc. has no trailing P/E on file, so the price is measured against sales instead: 5.25× revenue.
Price / sales · no trailing P/E on file: measured against sales instead
- Free cash flow yield
- 3.5%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +10%
Growth the price implies · The price pays for +10% free cash flow growth a year for a decade; revenue has grown 231% a year over the last three.
- Price / book
- 4.13
Price / book · as of 2026-Q2
Details›
- Price / bookas of 2026-Q2
- 4.13
- EV / EBIToperating margin −1.9%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $18M
- Market capitalisation34.7 million shares, counted Jul 31, 2026
- $500M
- 3-year revenue growth
- +231%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
What is it worth?
Today's price against what its own multiples, its cash flow and your growth assumption say it is worth.
Against its own past
Its multiples now against their own history, and how much of the price move came from earnings rather than the multiple.